Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
St. Jude Children's Research Hospital
Indiana University
University of Pittsburgh
Abramson Cancer Center at Penn Medicine
Bayer
Vedanta Biosciences, Inc.
UNC Lineberger Comprehensive Cancer Center
Eisai Inc.
MacroGenics
Virginia Commonwealth University
Arcus Biosciences, Inc.
Hoffmann-La Roche
Palleon Pharmaceuticals, Inc.
Incyte Corporation
Incyte Corporation
Genentech, Inc.
Novartis
NGM Biopharmaceuticals, Inc
Revolution Medicines, Inc.
Tvardi Therapeutics, Incorporated
University of Pittsburgh
MacroGenics
Labcorp Corporation of America Holdings, Inc
Inova Health Care Services
Sarcoma Oncology Research Center, LLC
BerGenBio ASA
Stanford University
Children's National Research Institute
Purple Biotech Ltd.
Eli Lilly and Company
Eli Lilly and Company
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
AstraZeneca
Natera, Inc.
National Cancer Institute (NCI)
Xencor, Inc.
Gene Surgery LLC
University of Southern California
Cedars-Sinai Medical Center
Exelixis
Eli Lilly and Company
Celldex Therapeutics
NextCure, Inc.
National Cancer Institute (NCI)
Sun Yat-sen University
National Institutes of Health Clinical Center (CC)
Deciphera Pharmaceuticals, LLC
M.D. Anderson Cancer Center
Sumitomo Pharma America, Inc.